CYCLO THERAPEUTICS, INC.: 10-K filed 2023-03-17
What CYCLO THERAPEUTICS, INC. reported in its annual report filed 2023-03-17 (fiscal FY 2022): 33 published measures, 67 facts as tagged in accession 0001437749-23-007064.
This filing
- Form
- 10-K (annual report)
- Filed
- 2023-03-17
- Fiscal period
- fiscal FY 2022
- Accession
- 0001437749-23-007064 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 4,215,213 | USD | |
| At 2021-12-31 | 19,520,833 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 734,544 | USD | |
| At 2021-12-31 | 15,671,863 | USD | |
| At 2020-12-31 | 10,452,482 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 1,543,418 | USD | |
| At 2021-12-31 | 16,612,711 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -15,450,888 | USD | 365 |
| 2021-01-01 to 2021-12-31 | -14,286,655 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -15,114,241 | USD | 365 |
| 2021-01-01 to 2021-12-31 | -15,005,298 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 15,086 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 22,500 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 6,778 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 18,757,074 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 38,170 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 14,822 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | -63,799,379 | USD | |
| At 2021-12-31 | -48,348,491 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 8,439,177 | shares | 365 |
| 2021-01-01 to 2021-12-31 | 6,370,073 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -1.83 | USD/shares | 365 |
| 2021-01-01 to 2021-12-31 | -2.24 | USD/shares | 365 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 0 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 0 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 55,188 | USD | |
| At 2021-12-31 | 59,583 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 354,056 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 295,578 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -15,621,886 | USD | 365 |
| 2021-01-01 to 2021-12-31 | -14,290,060 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 4,158,555 | USD | |
| At 2021-12-31 | 19,436,335 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 3,480,669 | USD | |
| At 2021-12-31 | 3,830,936 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 54,991 | USD | |
| At 2021-12-31 | 493,113 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 254,491 | USD | |
| At 2021-12-31 | 227,437 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 8,999,543 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 9,153,780 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 8,481,848 | shares | |
| At 2021-12-31 | 8,403,869 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 64,533,074 | USD | |
| At 2021-12-31 | 64,019,513 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 1,470 | USD | |
| At 2021-12-31 | 17,636 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 156,727 | USD | |
| At 2021-12-31 | 141,641 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 101,539 | USD | |
| At 2021-12-31 | 82,058 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 4,000 | USD | |
| At 2021-12-31 | 83,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -15,450,888 | USD | 365 |
| 2021-01-01 to 2021-12-31 | -14,286,655 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 19,481 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 16,827 | USD | 365 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 19,481 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 16,827 | USD | 365 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 12,474 | USD | 365 |
| 2021-01-01 to 2021-12-31 | -3,405 | USD | 365 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 0 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 3,525 | USD | 365 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -427,850 | USD | 365 |
| 2021-01-01 to 2021-12-31 | 444,023 | USD | 365 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 27,054 | USD | 365 |
| 2021-01-01 to 2021-12-31 | -10,472 | USD | 365 |
Inspect the source
- Entity
- CYCLO THERAPEUTICS, INC. / CIK 0000922247
- Captured
- 2026-09-21T17:17:43.874Z
- SEC response SHA-256
00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))